Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.2M | $50.0M | $43.0M | $29.4M | $35.4M | $11.6M | $0.00 | $0.00 |
| Revenue growth | — | 148.2% | -14.1% | -31.6% | 20.4% | -67.3% | -100.0% | — |
| Operating income | -$40.3M | -$54.1M | -$111M | -$188M | -$258M | -$487M | -$690M | -$1.18B |
| Operating margin | -200.0% | -108.2% | -257.5% | -639.7% | -730.0% | -4207.1% | — | — |
| Net income | -$41.8M | -$47.7M | -$108M | -$187M | -$249M | -$436M | -$600M | -$1.13B |
| Net margin | -207.2% | -95.2% | -251.6% | -636.6% | -703.0% | -3768.3% | — | — |
| EPS (diluted) | -$21.24 | -$22.33 | -$2.01 | -$2.57 | -$3.08 | -$3.86 | -$3.58 | -$5.95 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.21M | -$49.6M | -$100M | -$147M | -$224M | -$351M | -$557M | -$898M |
| Capital expenditures | $1.50M | $2.59M | $2.93M | $6.53M | $10.8M | $7.73M | $10.3M | $16.0M |
| Free cash flow | -$286K | -$52.2M | -$103M | -$154M | -$235M | -$358M | -$568M | -$914M |
| Dividends paid | — | — | $0.00 | — | — | — | — | — |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $69.6M | $16.7M | $104M | $108M | $161M | $696M | $543M | $384M |
| Total assets | — | $221M | $567M | $738M | $812M | $2.06B | $2.56B | $2.35B |
| Total liabilities | — | $68.0M | $92.7M | $135M | $127M | $236M | $293M | $723M |
| Shareholders' equity | -$108M | -$153M | $475M | $603M | $685M | $1.83B | $2.27B | $1.63B |
| Retained earnings | — | -$157M | -$266M | -$453M | -$701M | -$1.14B | -$1.74B | -$2.87B |
| Shares (wtd avg diluted) | — | 3.29M | 54.9M | 72.8M | 80.6M | 113M | 168M | 190M |
Every figure is extracted from Revolution Medicines, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.